Key Takeaways Esperion priced a 30M-share offering at $2.50, expecting$75M in gross proceeds.ESPR shares fell 17% as investors reacted to the discounted pricing of the new issue.Proceeds will fund Nexletol, Nexlizet expansion, pipeline work and general corporate needs.Esperion Therapeutics (ESPR) recently announced that it is floating a secondary issue of 30 million shares of its common stock to the public at an issue price of $2.50 per share. The company expects to raise approximately$75 million in gross ...